Impact of HER2 and PTEN simultaneous deregulation in non-small cell lung carcinoma: Correlation with biological behavior

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 12, 2012, Pages 6311-6311

  Panagiotou, Ioannis ^a   Georgiannos, Stavros N ^b   Tsiambas, Evangelos ^c   Karameris, Andreas ^d   Konstantinou, Marios ^e   Lazaris, Andreas C ^c   Kavantzas, Nikolaos ^c   Vilaras, George ^d   Patsouris, Efstratios ^c  

^a 401 GENERAL MILITARY HOSPITAL OF ATHENS   (Greece)

^b Blue Cross Hospital   (Greece)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^d NIMTS HOSPITAL   (Greece)

^e SOTIRIA GENERAL HOSPITAL   (Greece)

Author keywords

Gene; HER2 neu; Non Small cell lung carcinoma; PTEN

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PTEN PROTEIN, HUMAN;

ARTICLE; CHROMOSOME 17; DOWN REGULATION; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; LUNG TUMOR; LYMPH NODE; LYMPH NODE METASTASIS; MALE; METHODOLOGY; MIDDLE AGED; PATHOLOGY;

CARCINOMA, NON-SMALL-CELL LUNG; CHROMOSOMES, HUMAN, PAIR 17; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PTEN PHOSPHOHYDROLASE; RECEPTOR, ERBB-2;

EID: 84877085810     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.12.6311     Document Type: Article

References (37)

1. Au NH, Cheang M, Huntsman DG, et al (2004). Evaluation of immunohistochemical markers in non-small cell lung cancer by unsupervised hierarchical clustering analysis: a tissue microarray study of 284 cases and 18 markers. J Pathol, 204, 101-9.
2. Bendell JC, Rodon J, Burris HA, et al (2012). Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol, 30, 282-90.
3. Bepler G, Sharma S, Cantor A, et al (2004). RRM and PTEN as prognostic parameters for overalland disease-free survival in patients with non-small-cell lung cancer. J Clin Oncol, 22, 1878-85.
4. Cagle PT, Chirieac LR (2012). Advances in treatment of lung cancer targeted therapy. Arch Pathol Lab Med, 136, 504-9.
5. Chu EC, Tarnawski AS (2004). PTEN regulatory functions in tumor suppression and cell biology. Med Sci Monit, 10, 235-41.
6. Citri A, Yarden Y (2006). EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol, 7, 505-16.
7. Gatzemeier U, Groth G, Butts C, et al (2004). Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. Ann Oncol, 15, 19-27.
8. Hirsch FR, Varella-Garcia M, Franklin WA, et al (2002). Evaluation of HER-2/neu gene amplification and protein expression in nonsmall cell lung carcinomas. Br J Cancer, 86, 1449-56.
9. Jemal A, Bray F, Center M, et al (2011). Global Cancer statistics. CA Cancer J Clin, 61, 69-90.
10. Jin G, Kim MJ, Jeon HS, et al (2010). PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers. Lung Cancer, 69, 279-83.
11. Kang YH, Lee HS, Kim WH (2002). Promoter methylation and silencing of PTEN in gastric carcinoma. Lab Invest, 82, 285-91.
12. Lee SY, Kim MJ, Jin G, et al. (2010). Somatic mutations in epidermal growth factor receptor signaling pathway genes in non-small cell lung cancers. J Thorac Oncol, 5, 1734-40.
13. Lim WT, Zhang WH, Miller CR, et al. (2007). PTEN and phosphorylated AKT expression and prognosis in early- and late-stage non-small cell lung cancer. Oncol Rep, 17, 853-7.
14. Liu L, Shao X, Gao W, et al. (2010). The role of human epidermal growth factor receptor 2 as a prognostic factor in lung cancer: a meta-analysis of published data. J Thorac Oncol, 5, 1922-32.
15. Maira SM, Stauffer F, Schnell C, Garcia-Echeverria C (2009). PI3K inhibitors for cancer treatment: where do we stand. Biochem Soc Trans, 37, 265-72.
16. Marsit CJ, Zheng S, Aldape K, et al. (2005). PTEN expression in non-small-cell lung cancer: evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration. Hum Pathol, 36, 768-76.
17. Meert AP, Martin B, Paesmans M, et al. (2003). The role of HER-2/neu expression on the survival of patients with lung cancer: a systematic review of the literature. Br J Cancer, 89, 959-65.
18. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA (2008). Non-Small Cell Lung Cancer: Epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc, 83, 584-94.
19. Nagata Y, Lan KH, Zhou X, et al. (2004). PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell, 6, 117-27.
20. Nakamura H, Saji H, Ogata A, et al. (2003). Correlation between encoded protein overexpression and copy number of the HER2 gene with survival in non-small cell lung cancer. Int J Cancer, 103, 61-6.
21. O'Byrne KJ, Gatzemeier U, Bondarenko I, et al. (2011). Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study. Lancet Oncol, 12, 795-805.
22. Olaussen KA, Soria JC, Mřat L, et al. (2003). Loss of PTEN expression is not uncommon but lacks prognostic value in stage I NSCLC. Anticancer Res, 23, 4885-90.
23. Pelosi G, Del CB, Dell'Orto P, et al. (2005). Lack of prognostic implications of HER-2/neu abnormalities in 345 stage I non-small cell carcinomas (NSCLC) and 207 stage I-III neuroendocrine tumours (NET) of the lung. Int J Cancer, 113, 101-8.
24. Perez EA, Reinholz MM, Hillman DW, et al. (2010). HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial. J Clin Oncol, 28, 4307-15.
25. Sher T, Dy GK, Adjei AA (2008). Small cell lung cancer. Mayo Clin Proc, 83, 355-67.
26. Shoman N, Klassen S, McFadden A, et al. (2005). Reduced PTEN expression predicts relapse in patients with breast carcinoma treated by tamoxifen. Mod Pathol, 18, 250-9.
27. Song MS, Salmena L, Pandolfi PP (2012). The functions andCell Biol, 13, 283-96.
28. Swanton C, Futreal A, Eisen T (2006). Her2-targeted therapies in non-small cell lung cancer. Clin Cancer Res, 12, 4377-83.
29. Takenaka M, Hanagiri T, Shinohara S, et al. (2011). The prognostic significance of HER2 overexpression in non-small cell lung cancer. Anticancer Res, 31, 4631-6.
30. Tan D, Deeb G, Wang J, et al. (2003). HER2 protein expression and gene alteration in stage I-IIIA non-small-cell lung cancer: a study of 140 cases using a combination of high throughput tissue microarray, immunohistochemistry, and fluorescent in situ hybridization. Diagn Mol Pathol, 12, 201-11.
31. Tang JM, He QY, Guo RX, et al. (2006). Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis. Lung Cancer, 51, 181-91.
32. Timotheadou E, Skarlos DV, Samantas E, et al. (2007). Evaluation of the prognostic role of a panel of biomarkers in stage IB-IIIA non-small cell lung cancer patients. Anticancer Res, 27, 4481-9.
33. Valabrega G, Montemurro F, Aglietta M (2007). Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol, 18, 977-84.
34. Vogel CL, Cobleigh MA, Tripathy D, et al. (2002). Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol, 20, 719-26.
35. Wang L, Zhang Q, Zhang J, et al. (2011). PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib. BMC Cancer, 11, 248.
36. Wang L, Yue W, Zhang L, et al. (2012). mTOR and PTEN expression in non-small cell lung cancer: analysis by real-time fluorescence quantitative polymerase chain reaction and immunohistochemistry. Surg Today, 42, 419-25.
37. Yoo SB, Xu X, Lee HJ, et al. (2011). Loss of PTEN expression is an independent poor prognostic factor in non-small cell lung cancer. Korean J Pathol, 45, 329-35.